

JAN 22 2001

Commissioner for Patents United States Patent and Trademark Office Washington, D.C. 20231 www.uspto.gov

David J. Levy, Ph.D.
Patent Counsel
Glaxo Wellcome Inc.
Five Moore Drive
Research Triangle Park, NC 27709

Re: Pat

Patent Term Extension

Application for

U.S. Patent No. 4,997,841

Dear Mr. Levy:

A certificate under 35 U.S.C. § 156 is enclosed extending the term of U.S. Patent No. 4,997,841 for a period of 694 days. While a courtesy copy of this letter is being forwarded to the Food and Drug Administration (FDA), you should directly correspond with the FDA regarding any required changes to the patent expiration dates set forth in the Patent and Exclusivity Data Appendix of the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) or in the Patent Information set forth in the Green Book (FDA Approved Animal Drug Products).

Telephone inquiries regarding this communication should be directed to the undersigned at (703)306-3159.

Karin Tyson

Senior Legal Advisor

Office of Patent Legal Administration

Office of the Assistant Commissioner for Patent Examination Policy

cc: David T. Read

Re: AMERGE™ (naratriptan hydrochloride)

Acting Director Regulatory Policy Staff, CDER FDA Docket No. 95E-0614

Food and Drug Administration 1451 Rockville Pike, HFD-7

Rockville, MD 20852

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE EXTENDING PATENT TERM UNDER 35 U.S.C. § 156

PATENT NO.

4,997,841

ISSUED

March 5, 1991

INVENTORS

Alexander W. Oxford, et al.

PATENT OWNER

Glaxo Wellcome Inc.

PRODUCT

AMERGE® (naratriptan hydrochloride)

This is to certify that an application under 35 U.S.C. § 156 has been filed in the U.S. Patent and Trademark Office, requesting extension of the term of U.S. Patent No. 4,997,841 based upon the regulatory review of the product AMERGE® (naratriptan hydrochloride) by the Food and Drug Administration. Since it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

694 days

from August 12, 2008, the original expiration date of the patent, subject to the provisions of 35 U.S.C. § 41(b), with all rights pertaining thereto as provided by 35 U.S.C. § 156(b).



I have caused the seal of the U.S. Patent and Trademark Office to be affixed this 19th day of January 2001.

O. Todd Dickinson

Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office